Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Operating Margin (2022 - 2026)

TriSalus Life Sciences has reported Operating Margin over the past 5 years, most recently at 94.52% for Q1 2026.

  • For Q1 2026, Operating Margin fell 1457.0% year-over-year to 94.52%; the TTM value through Mar 2026 reached 62.45%, up 3656.0%, while the annual FY2025 figure was 59.68%, 6320.0% up from the prior year.
  • Operating Margin for Q1 2026 was 94.52% at TriSalus Life Sciences, down from 24.77% in the prior quarter.
  • Over five years, Operating Margin peaked at 24.77% in Q4 2025 and troughed at 364.91% in Q4 2022.
  • A 5-year average of 174.09% and a median of 118.91% in 2024 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: plummeted -15173bps in 2023 and later surged 23957bps in 2024.
  • Year by year, Operating Margin stood at 364.91% in 2022, then soared by 32bps to 249.05% in 2023, then soared by 63bps to 91.76% in 2024, then skyrocketed by 73bps to 24.77% in 2025, then plummeted by -282bps to 94.52% in 2026.
  • Business Quant data shows Operating Margin for TLSI at 94.52% in Q1 2026, 24.77% in Q4 2025, and 77.94% in Q3 2025.